News | April 22, 2024
Vertex announces advancements of Suzetrigine in acute and neuropathic pain
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Submission based on results from pivotal phase III trial showing all primary endpoints met
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
It is the first autotaxin inhibitor to be investigated in cancer patients
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The validations confirm the completion of the applications and commence the scientific review process
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
